Well the new CEO starts Monday so he can sign and date! |
On the Butterfield timing, CMA appeal is 7 months overdue and the CMA clearly stated that not being aware is no excuse. Wouldn't surprise me if Butterfield is disqualified from acting as a director so has the post of CEO in name only and can't sign off the accounts. So all a bit of an administrative mess affecting the audit and the search for a replacement taking longer than planned. |
Repeat - they need to sort out the mess with Deloitte and compromise is a must.
H1 is almost ending - these results are to December end. Forward guidance is all important.
Historically APH has traded at 15x P/E, now down to 8x. |
Who have bought at dip ? Well done , likely go up towards 70p direction. Up on account publication it will be double |
Sudden avalanche of negative bs
whif of burning opportunistic short spread betters
which is nice |
Excellent day today , backing up again |
Part of the uncertainty is that they haven't even suggested a new date; maybe they don't want the further ignominy of failing to deliver again. Butterfield departure is obviously highly suspicious in timing , hard to imagine that is not unconnected; though the comment that the January update is still accurate clearly has not reassured the market. Except Blackhorse , whose predictions have become more and more desperate and dubious. |
No traders are selling big time, I'm afraid. |
Shorts are closing & buyers are back |
Common sense and compromise needs to prevail between Deloitte and the board. Or find an alternative. |
Loads of 500k block buying, something brewing |
500K buys x 5
Dbay hold a significant stake here. Likely adding. |
Last chance to buy below 30p |
It’s been dodgy as a dodgy thing for years |
This looks awful tbh debts and not making money on 180m of sales with a pipeline of old drugs way past there sell by date na being suoerceeded. I suspect there are serious issues here hence delayed results.
Chart points to a possible disaster coming this way to. Be very carful listening to the Rampers they usually get it wrong.
For now I'll happily watch from the sidelines until we see results and see just what the issues are besides a very poor business plan |
Chart suggests it's going lower. Best to wait for the next newsflow before any purchase. |
Hearing this could be the next zero. Sad for holders. |
This is risky while the bid are making changes and no reuslts published. Is it there is something nasty lurking, I have seen this before so wouldn't want to be holding shares at this time until things become clear,simply not worth the risk.
I'll keep it on my watch list but expect this to continue to fall until we see the results and what's going on |
Very true, I've said many times theres better opportunities but maybe the lows today were an opportunity, I don't and have never looked deep enough, just stating to others to ignore constant spam posting and Dyor etc etc etc. say it again, hopefully this turns around for genuine people |
Lucky who bought at dip |
Is it?
Wild speculation.
It could just as easily receive another takeover offer (or two) here sat at 2012 lows. |
 FT - 8/5/24:
Sedgwick will have to turn around flagging performance at the company. In an unaudited trading update in January, Alliance cut its profit expectations for 2024 to 18 per cent below analyst estimates, saying that it would need to expand investments in sales and marketing to increase revenues, which were £182.7mn in 2023.
The business has spent £380mn on acquisitions since it listed in 2003, according to Jantet, buying up old medicine brands that it then tried to turn around. This increased debt levels to 2.7x earnings in 2022, although analysts anticipate this level will have fallen in the 2023 results and Jantet said current debt levels were not “concerning221;.
Despite its outlay on new products, few have proved successful, said Miles Dixon, an analyst at Peel Hunt. Scar treatment Kelo-Cote accounted for more than a third of total revenue, according to the January update, in a portfolio of about 80 brands.
“If Kelo-Cote slows down, it’s the only growth product. If they were to refinance debt, it’d be expensive,” Dixon added.
The share price fall on Wednesday brings the total decline in the past year to 62.5 per cent, hitting the company’s many UK investors.
“It’s traditionally been a story that’s popular with UK fund managers. It’s easy to explain, traditionally pays a dividend, and has lots of analyst coverage,” Dixon said. “It’s an indictment of UK thinking to stick with something like this rather than look at more specialist healthcare stories,” such as high-growth biotech companies.
=====
The Amberen deal at $110m was horrific and collapsed the share price. Is the market pricing in a rights issue to strengthen the balance sheet? |
Be greedy when others are fearful?
Pharmaceutical company trading at 6x earnings and half NAV?
(Unless KPMG and Deloitte have both been signing off completely bogus accounts for the last decade). |
You still buying more ffs sheeesh tr1 coming??? |
Account will be publishing anyway & it will be accurate as mentioned 29th January , so all good |
Register for real-time alerts, custom portfolio, and market movers
Hot Features
Premium
